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Abstract
Aim Nivolumab, a fully human immunoglobulin G4 pro-
grammed death-1 (PD-1) immune checkpoint inhibitor
antibody, has activity in melanoma, non–small-cell lung
cancer (NSCLC), renal cell carcinoma (RCC), and Hodg-
kin lymphoma. Nivolumab is approved in the USA and EU
for advanced melanoma, NSCLC, and RCC, and relapsed
Hodgkin lymphoma in the USA. Programmed death-ligand
1 (PD-L1), a PD-1 ligand, is expressed on mononuclear
leukocytes, myeloid cells, and tumor cells. PD-L1 is being
investigated as a potential biomarker to predict the asso-
ciation of tumor PD-L1 expression with nivolumab
efficacy.
Methods Bristol-Myers Squibb and Dako previously
reported on an automated PD-L1 immunohistochemical
(IHC) assay that detects cell surface PD-L1 in formalin-
fixed, paraffin-embedded, human tumor tissue specimens
using Dako’s Autostainer Link 48. The primary antibody
for this assay is a rabbit monoclonal antihuman PD-L1
antibody, clone 28-8. Another rabbit monoclonal antihu-
man PD-L1 antibody, clone E1L3N, was compared with
28-8 for specificity and sensitivity using an identical
detection method followed by vendor-recommended
detection methods.
Results Using PD-L1 null clones of L2987 and ES-2 tumor
cell lines, both antibodies were specific for detection of
PD-L1 on the plasma membrane, although E1L3N also
stained cytoplasm in ES-2 knockout cells. Using the
identical method, E1L3N was slightly more sensitive than
28-8 based on staining intensities. Using manufacturer-
recommended detection methods and predefined scoring
criteria for plasma membrane staining of tumor and
immune cells, 28-8 demonstrated significantly improved
detection compared with E1L3N.
Conclusions Epitope retrieval and highly sensitive
detection reagents are key determinants in IHC detection of
PD-L1.
Key Points
Rabbit monoclonal anti-programmed death-ligand 1
(anti–PD-L1) antibodies clone 28-8 and E1L3N both
demonstrated PD-L1 target specificity (E1L3N, only
at the plasma membrane).
Sensitivity of the two antibodies was comparable
when an identical immunohistochemical retrieval
and detection method was used; however, detection
significantly improved with 28-8 versus E1L3N
using manufacturer-recommended methods specific
for each antibody.
Epitope retrieval and sensitive detective reagents are
important for achieving optimal target specificity and
sensitivity.
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1 Introduction
Nivolumab, a fully human immunoglobulin (Ig) G4 pro-
grammed death-1 (PD-1) immune checkpoint inhibitor
antibody, is approved in the USA for unresectable or
metastatic melanoma alone or in combination with ipili-
mumab, advanced renal cell carcinoma (RCC) after prior
antiangiogenic therapy, metastatic non–small-cell lung
cancer (NSCLC) after progression on or after platinum-
based chemotherapy, and relapsed or progressive classical
Hodgkin lymphoma following autologous hematopoietic
stem cell transplantation and brentuximab vedotin [1]. It is
approved in the EU for unresectable or metastatic mela-
noma alone or in combination with ipilimumab, advanced
RCC after prior therapy, and locally advanced or metastatic
NSCLC after prior chemotherapy [2]. PD-1 and its ligands
are checkpoint regulators in immune cells [3–6]. Pro-
grammed death-ligand 1 (PD-L1), one of the two PD-1
ligands, can also be expressed on the surface of tumor cells
as a potential mechanism to engage PD-1 on the surface of
the effector immune cells and evade an antitumor immune
response [7–10]. The expression of PD-L1 has been
reported on tumor cells in NSCLC and melanoma, among
other tumor types [10–16]. Immunoassays employing dif-
ferent primary antibodies, assay formats, and scoring
approaches to assess the prevalence of positive PD-L1
expression in NSCLC, melanoma, and RCC have been
reported [7, 8, 10, 16–18], although few of these reports
have directly compared the impact of antibody specificity
and detection sensitivity [18]. Studies have shown that
antibodies developed against PD-L1 show variable ability
to detect PD-L1 in the cell plasma membrane compartment
compared with the cytoplasm compartment [19, 20]. Some
antibodies may not even be wholly specific for PD-L1 [18].
In the present study, we compare the specificity and sen-
sitivity of the antibodies clone 28-8 and clone E1L3N, to
evaluate the performance of the validated Bristol-Myers
Squibb (BMS) and Dako assay (PD-L1 IHC 28-8
pharmDx) and the Cell Signaling Technology (CST) assay.
The PD-L1 IHC 28-8 pharmDx assay is approved by the
US Food and Drug Administration (FDA) as a comple-
mentary diagnostic for non-squamous NSCLC and mela-
noma in the USA and CE marked in the EU.
2 Materials and Methods
2.1 Generation of Antibodies 28-8 and E1L3N,
Tumor Cell Lines and Tumor Samples
The rabbit monoclonal antihuman PD-L1 antibody 28-8
was produced by Abcam (lot #3), and the rabbit
monoclonal antihuman PD-L1 antibody E1L3N by CST.
Commercial tissue samples as well as L2987 and ES-2
parent cell lines and their respective knockout cell lines,
L2-14 and T1-11, were used for specificity testing. In-
frame translation stop codons in L2987 and ES-2 cells
were introduced via genetic editing to create clones of
L2987 and ES-2 that were null of PD-L1. A transcription
activator-like effector nuclease (TALEN) genomic tar-
geting approach was employed. A TALEN pair that
recognizes a sequence common to all expressed isoforms
within the fourth exon of the PD-L1 gene (Cd274) was
designed and constructed at Cellectis (Paris, France)
[21]. Tonsil and squamous head and neck carcinoma
samples were used for sensitivity testing. Tonsil,
NSCLC, and squamous head and neck carcinoma spec-
imens were from Asterand Biosciences (Detroit, Michi-
gan), and melanoma specimens were from MT Group
(Van Nuys, California).
2.2 Immunohistochemical Procedures
In the first testing procedure, specimens were epitope
retrieved and tested using an identical BMS-developed
procedure (see the electronic supplementary material,
Supplemental Table 1a). Briefly, the specimen slides were
de-paraffinized and rehydrated as follows: xylene,
2 9 5 min; 100 % ethanol, 2 9 2 min; 95 % ethanol,
2 9 2 min; 70 % ethanol, 2 9 2 min; distilled water,
1 9 2 min. The antigen retrieval process was performed
with the Target Retrieval Solution (pH 6.0, Dako) at
110 C for 10 min in the Decloaking Chamber (Biocare
Medical). Slides were then stained with the Novolink
Polymer kit (Leica Biosystems) on the BioGenex i6000
autostainer. Visual assessments were conducted with
photographs of the same region on serial sections. E1L3N
was sourced from CST, while 28-8 was from a lot man-
ufactured by Abcam for BMS. A negative control rabbit
IgG was used and did not show any staining (data not
shown).
In the second testing procedure, each antibody was
assessed using the manufacturer-recommended detection
methods on test commercial clinical samples. The 28-8
antibody was tested using Dako PD-L1 IHC 28-8 pharmDx
(Dako North America; SK005) and the Dako-recom-
mended protocol, as previously described [21]. For the PD-
L1 IHC 28-8 pharmDx assay, tumor tissue sections were
de-paraffinized and antigen-retrieved at 97 C for 20 min
in the PT Link. Detection of PD-L1 protein was conducted
using 2 lg/mL of the antibody on the Autostainer Link 48
according to Dako instructions (Supplemental Table 1a).
The E1L3N antibody was tested using the CST-recom-
mended protocol, as previously described (CST #13684
PD-L1 E1L3N XP Rabbit mAb Technical sheet). For
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E1L3N, the manufacturer did not specify a heat-induced
epitope retrieval (HIER) condition; therefore, samples were
tested at 110 C for 10 min and 97 C for 20 min. Because
110 C for 10 min (the original condition used in speci-
ficity tests) showed improved sensitivity over 97 C for
20 min, this condition was retained for E1L3N (Fig. 1a, b).
Immunohistochemistry (IHC) was conducted according to
manufacturer specifications using 3.5 lg/mL of the anti-
body with the CST-recommended SignalStain detection kit
(Supplemental Table 1a).
2.3 Analysis
The sensitivity of each manufacturer’s protocol was
evaluated by linear cell surface staining of tumor and
immune cells, including both circumferential and non-
circumferential staining. Tumor PD-L1 expression was
evaluated using the histoscore method, and pathologists
were encouraged to score in 1 % increments in the
1–10 % range. PD-L1 expression on immune cells was
evaluated by its frequency and scored as absent (0), rare
(1), moderate (2), or intense/diffuse (3). A single trained
pathologist (DMC) was blind to the identity of the
antibodies and protocols. The antibodies were evaluated
in sequence, with a 1-month washout period between
evaluations. In addition, two independent trained
pathologists (JS and MB) evaluated each stain separately
and then convened to compare significant differences. A
comparison of the manufacturer-recommended protocols
reveals differences among the protocols, including a
higher concentration of the E1L3N antibody and differ-
ent reagents in each detection kit (Supplemental
Table 1a, b).
3 Results
3.1 Target Specificity Using Identical Detection
Conditions
To test the specificity of the E1L3N antibody for PD-L1,
genetic deletion of PD-L1 [21] was tested on L2987 and
ES-2 cells using a HIER and detection condition that was
optimal for both antibodies (see Sect. 2). Rabbit mono-
clonal antibody (mAb) 28-8 is specific for its human PD-
L1 target in L2987 (Fig. 2a–d) and ES-2 cells (Fig. 2e–h).
This is evidenced by the loss of cell surface staining in cells
where the expression of PD-L1 has been eliminated by a
TALEN-induced double-stranded break within the fourth
exon of the gene and the subsequent creation of an in-frame
translational stop codon by the repair process of non-ho-
mologous end jointing (NHEJ). E1L3N stains the plasma
membrane of parental L2987 and ES-2 cells, but not in
cells null for PD-L1 expression. However, detection of
cytoplasmic staining remained in 5 % of PD-L1 null ES-2
cells (Fig. 2h). These experiments demonstrate that 28-8
and E1L3N are specific for cell surface PD-L1, but that
E1L3N may also recognize another unrelated, non–PD-L1
antigen within the cytoplasm. Cytoplasm staining in tissues
not expected to express PD-L1 has been seen by others,
albeit at much higher concentrations of E1L3N than was
used in this study [22].
3.2 Sensitivity Using Identical Detection Conditions
E1L3N was compared with 28-8 using the same protocol to
allow evaluation under identical detection conditions. Both
antibodies were tested on chronic tonsillitis and squamous
Fig. 1 Target retrieval is better
at b 110 C for 10 min
compared with a 97 C for
20 min in the melanoma
028-MT0261-61 sample
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head and neck carcinoma samples. In the tonsil samples,
both antibodies stained follicular and interfollicular
mononuclear cells as well as crypt epithelium spindloid
cells, which resemble macrophages and dendritic cells.
Both antibodies also stained the plasma membrane of the
squamous head and neck tumor. Staining was similar for
both antibodies, although E1L3N stained 40 % of tumor
cells (vs. 25 % with 28-8) and exhibited slightly higher
intensities for cells of both epithelial (Fig. 3a–d) and
immune cell origin (Fig. 3e, f).
Fig. 2 a–d Intrinsic specificity
of L2987 and KO cell lines:
both E1L3N and 28-8 appear to
be specific to PD-L1, as all
staining is completely
eliminated in the L2987 KO cell
line. Both 28-8 and E1L3N were
tested at 2 lg/mL. e–h Intrinsic
specificity of ES-2 and KO cell
line: both E1L3N and 28-8
appear to be specific to PD-L1,
as all plasma membrane staining
is eliminated in the L2987 KO
cell line; however, some
cytoplasm staining remains with
E1L3N. 28-8 concentration was
increased to 3 lg/mL so
staining intensity was
equivalent to E1L3N at 2 lg/
mL. Ab antibody, KO knockout,
PD-L1 programmed death-
ligand 1
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3.3 Detection Using Manufacturer-Recommended
HIER and Detection
Antibodies 28-8 and E1L3N were compared using manu-
facturer-recommended methods on a set of 20 NSCLC and
20 melanoma specimens exhibiting a range of PD-L1
expression (Supplemental Table 2). The assays were first
compared using a blinded test performed by a single
pathologist, with a 1-month washout to discern differences
independent of reader bias that may occur between
pathologists. Despite using an improved epitope retrieval
condition ahead of the E1L3N manufacturer-recom-
mended detection method, we still noted higher sensitivity
in staining of PD-L1 using the Dako PD-L1 IHC 28-8
pharmDx retrieval and detection method. The percentage
of PD-L1–positive (PD-L1?) tumors (Supplemental
Table 2) and immune cell PD-L1 staining frequency
(Supplemental Table 3) varied for the set of 20 NSCLC
and 20 melanoma specimens. The distribution of the PD-
L1? tumor staining (Fig. 4a, b) and immune cell
Fig. 3 Intrinsic sensitivity. a,
b Staining of head and neck
tumor cells is slightly higher
with E1L3N compared with
28-8, although overall intensity
does not shift out of 1?
intensity. c, d Staining intensity
of tonsil crypt epithelium was
slightly higher with E1L3N
relative to 28-8. e, f E1L3N has
slightly greater intrinsic
sensitivity on lymphoid and
spindloid cells. PD-L1
expression in tingible body
macrophages homing the
germinal centers in secondary
follicles is similar between 28-8
and E1L3N. Ab antibody, PD-
L1 programmed death-ligand
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frequencies (Fig. 5a, b) are shown in both tumor types.
The percentage of PD-L1? tumors detected by the Dako
28-8 assay was in the expected range for both NSCLC
[21] and melanoma (publication pending). On matched
samples, the PD-L1 IHC 28-8 pharmDx assay more fre-
quently detected PD-L1? tumor (22 vs. 6) and PD-L1?
immune cells (15 vs. 7) compared with the E1L3N CST
assay. The average difference across all specimens was
higher for the PD-L1 IHC 28-8 pharmDx assay than the
E1L3N CST assay for the percentage of PD-L1? tumor
staining (20 vs. 3) and PD-L1? immune cell frequency
(1.27 vs. 1; Table 1). In specimens in which the E1L3N
CST assay was scored higher for the percentage of PD-L1
tumor, the margin was only 1–5 % greater. Compared
with E1L3N, 28-8 scored higher for all parameters in both
tumor types except melanomas, in which PD-L1? tumors
were detected in equal numbers. Four representative
images for NSCLC and melanoma that demonstrate dif-
ferences in frequency and staining of the plasma mem-
brane between the PD-L1 IHC 28-8 pharmDx assay and
the E1L3N CST assay are shown in Supplemental Fig-
ures 1–4. In addition, when two independent pathologists
reviewed each assay (Table 2 and Supplemental Table 2),
the results similarly favored 28-8 Dako pharmDx versus
E1L3N CST assay [percentage PD-L1? tumor average
difference (18 vs. 7) and number of tumors identified as
PD-L1? (19 vs. 13)], and PD-L1? immune cell density
scores (1.24 vs. 1).
4 Discussion
Many companies and academic laboratories are developing
antibodies to detect PD-L1 as a potential predictive marker
for therapies that interfere with the interaction of one or
both of the PD-1 ligands with the PD-1 receptor. PD-L1 is
expressed on a subset of tumors in many but not all his-
tologies, as well as on immune cells, predominantly the
mononuclear leukocytes and monocytes/macrophages that
are present in most tumors. IHC assays must be developed
that can detect PD-L1 across a large dynamic range and
still retain sensitivity for low levels of PD-L1 expression,
especially in tumors.
Genetic deletion in cell lines was previously used to
demonstrate the specificity of rabbit mAb 28-8, an antibody
developed by BMS in collaboration with Abcam and Dako.
The present study compares the specificity of 28-8 with
E1L3N, a rabbit mAb developed by CST. Both 28-8 and
E1L3N are specific for cell surface PD-L1, as evidenced by
lack of staining following genetic deletion in L2987 and
ES-2 cells. However, the cytoplasm staining of ES-2






























































































































































































































































































































































































































E1L3N PD-L1+ A B
Fig. 4 a Tumor plasma membrane scoring of NSCLC samples. b Tumor plasma membrane scoring of melanoma samples. NSCLC non–small-
cell lung cancer, PD-L1 programmed death-ligand
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with 28-8, suggesting this CST antibody may also recognize
a non–PD-L1 protein. Most PD-L1 testing has focused on
cell surface staining. Strong cytoplasm staining, when
present, can confound assessment of plasma membrane
staining. While we cannot directly address whether the
remaining cytoplasm staining in ES-2 cells has implications
for tissue testing, pathologists were able to detect plasma
membrane staining with the E1L3N laboratory developed
test (LDT) without interference from cytoplasmic staining.
The intrinsic sensitivity of both antibodies was com-
pared using an identical HIER condition, antibody con-
centration, and signal detection method. Using this
methodology, E1L3N has slightly higher intrinsic sensi-
tivity, as it stains more cells than 28-8 when tested on tonsil
(epithelium in crypts, spindloid cells in follicles, and
mononuclear leukocytes in follicle and interfollicular
areas) and squamous head and neck tumor cells.
We also compared the performance of manufacturer-
recommended detection methods provided by Dako and
CST. CST recommends SignalStain Detection, whereas
Dako has a proprietary linker antibody in their PD-L1 IHC
28-8 pharmDx detection kit. Under these manufacturer-
recommended testing protocols, the detection of PD-L1














































































































































































































































































































































































































































Fig. 5 a Immune cell plasma membrane scoring of NSCLC samples. b Immune cell plasma membrane scoring of melanoma samples. NSCLC
non–small-cell lung cancer, PD-L1 programmed death-ligand
Table 1 Single pathologist comparative analysis of the percentage of PD-L1? tumors and immune scoring








PD-L1? immune cell frequency
score difference (0, 1, 2, 3)
minimum/maximum (average)
PD-L1 IHC 28-8 pharmDx[CST 22 1/60 (20) 15 1/3 (1.27)
CST[PD-L1 IHC 28-8 pharmDx 6 1/5 (3) 7 1/1 (1)
Equal 12 0/0 18 0/0
CST cell signaling technology, IHC immunohistochemical, PD-L1 programmed death-ligand 1
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number of PD-L1? tumors detected, number of specimens
with higher scores, and average increase in the percentage
of positive tumors. The detection of PD-L1 tumor was
higher for 28-8 versus E1L3N, whether evaluated by a
single pathologist in sequence or by two separate pathol-
ogists reading each assay independently. The 28-8 antibody
was scored higher in melanoma tumor cells for all
parameters except PD-L1? tumor frequency. However,
pathologists noted that the evaluation of PD-L1? tumors
can be challenging in the 1–5 % range when abundant PD-
L1? histiocytes are present. This was more apparent in
melanomas for present/absent calls when independent
pathologists were reading each assay. Inclusion of stains
that identify tumors or histiocytes may aid pathologists in
their evaluation process for future studies.
This study was limited by sample size and scope. The
size of the tumor sample set used for the comparison of the
E1L3N and 28-8 antibodies was small. Larger sample sets
(with additional tumor types) are required for a more
accurate quantitative comparison, and will allow for other
types of analyses such as comparing PD-L1 positivity at
specified cutoffs. This study was also limited in scope to
the comparison of two PD-L1 antibodies among several
that are currently in use for LDT and diagnostic assays.
Additional comprehensive analyses of these PD-L1 anti-
bodies are needed, preferably on a common assay platform.
This study demonstrates the advantages of the 28-8
antibody with regard to absolute target specificity and
sensitivity using the Dako recommended HIER and
detection protocols. Decreased ability to detect cell surface
PD-L1 by this CST LDT compared with the Dako
pharmDx method has implications for the assessment of
PD-L1 expression in patient samples attained for clinical
diagnosis. Those laboratories wishing to use LDTs instead
of companion diagnostic tests should carefully select the
clone and detection method to ensure target specificity and
sensitivity. E1L3N should not be used before nivolumab
administration as this antibody is not part of a standardized
assay/kit that has been analytically and clinically validated
(utilized in nivolumab clinical trials) and approved by any
regulatory organization. It is important that in vitro
predictive and/or prognostic diagnostic assays used to
inform clinical treatment decisions are fully validated and
meet appropriate standards. Failure to achieve these stan-
dards may lead to inaccurate assay results and cause mis-
interpretation of potential clinical outcomes associated
with PD-1 checkpoint inhibitor treatment.
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